

For Immediate Release:

Contact: Kristine Ashcraft
Genelex Corporation – Seattle, WA
800 523-3080 or 206-826-1957

**Genelex, a pioneer in personalized medicine,
announces development of test that maximizes
antidepressant treatment success.**

(SEATTLE) -- Testing of a person's genetic ability to create enzymes in the liver called CYP2D6 and CYP2C19 that processes virtually all antidepressants have been available for several years to aide healthcare providers in optimizing patient's response to antidepressants, but Genelex has recently developed another test that can help maximize treatment success.

In a recent statement, Dr. Teresa Aulinskas, Genelex Chief Scientific Officer remarked, "I am excited to give medical providers another tool that will help them better target therapy in the treatment of depression when finding the right drug and dose as early as possible is so critical."

The new test available from Genelex helps determine a person's response to serotonin-selective reuptake inhibitors (SSRIs) which are among the most commonly prescribed antidepressants. This class of medications includes citalopram, fluoxetine, paroxetine and sertraline among others, and often is prescribed for depression or anxiety.

For a number of reasons some people may not respond as well as others to this class of drugs. Each person's unique genetic make-up affects how their body absorbs, modifies and ultimately excretes any medication taken, but genetics also play a role in how a drug will exert its effect within the body. Researchers have found that mutations in some genes specifically change how effectively SSRIs may act.

DNA testing may offer the key to avoiding failure of antidepressants in many cases. To learn more about the use of DNA Testing in the treatment of depression, visit <http://www.healthanddna.com/drug-safety/depression.html>.

For further information about the DNA testing, contact Kristine Ashcraft at Genelex, 800 523-3080 or 206-826-1957.